Fig 1: NF-κB p65 and HDAC2 are highly expressed in the dorsal horn of the CCI rat spinal cord. a PWT and PWL measured in the dorsal horn of CCI rats (n = 10), normal rats (n = 10), and sham-operated rats (n = 10). b, c Protein levels of NF-κB p65 and HDAC2 in dorsal horn of CCI rat spinal cord at different time points following CCI modeling determined by Western blot analysis, normalized to GAPDH. d Expression of NF-κB p65, NF-κB p-p65, and HDAC2 with Iba-1-labeled microglial cells of CCI rat spinal cord detected by immunofluorescence staining. Iba-1 is a marker molecule of microglial cells. Image J software was used to analyze the IOD (scale bar = 25 μm). *relative to sham-operated or normal rats indicates p < 0.05. All measurement data were expressed as the mean ± standard deviation. Unpaired t test was used to analyze data between the two groups, one-way ANOVA and Tukey’s post hoc test to analyze data among multiple groups, and repeated-measures ANOVA with Bonferroni post hoc test to analyze data at different time points
Fig 2: Modulation of lamin A/C-HDAC2 interaction by statins. (A) Co-immunoprecipitation of lamin A/C and HDAC2 in the presence or absence of mevinolin as indicated in the legend. A representative western blot is shown. Molecular weight markers are indicated in kDa. Densitometric analysis of immunoprecipitated HDAC2 bands is reported in the graph. Statistical significance (p < 0.01) is indicated. (B) PLA of lamin A/C and HDAC2 or prelamin A and HDAC2 in human dermal fibroblasts left untreated (NT) or treated with mevinolin (Mevinolin). Nuclei are counterstained with DAPI. Quantitative analysis of PLA signals (red dots) is reported in the graphs. Statistical significance (p < 0.05) is indicated.
Fig 3: HDAC3 protein staining in normal human pituitaries and NFPAs. (A) Representative immunohistochemical staining images of HDAC3 protein in 2 NPs and 4 NFPAs. (B) HDAC3 immunostaining was quantified on the basis of color intensity of converted photos (40x) to a subtractive color model CMYK and split into green/red/yellow/blue channels. The intensities were averaged from 100 selected nuclei. (C) Representative immunohistochemical staining images of HDAC2 protein in 2 NPs and 2 NFPAs. (D) HDAC2 immunostaining was quantified on the basis of color intensity of converted photos (40x) to a subtractive color model CMYK and split into green/red/yellow/blue channels. The intensities were averaged from 100 selected nuclei. NP, normal pituitary; NFPA, non-functioning pituitary adenoma; *P < 0.05; **P < 0.001.
Fig 4: HDAC2 interacted with miR-204-5p to regulate Bcl-2 expression(A) Overlapping miRNAs potentially binding to Bcl-2 transcripts were predicted by Venn diagram. Two miRNAs, miR-204-5p and miR-211-5p, were predicted to participate in HDAC2-mediated regulation of Bcl-2 expression. (B) The level of miR-204-5p increased in HEI-OC1 cells transfected with si-HDAC2 (∗∗p < 0.01), while the mRNA of miR-211-5p was not significantly changed (N.S. indicates not significant). (C) The level of miR-204-5p was significantly increased in the cochleae derived from LPS-treated guinea pigs compared to controls (∗∗p < 0.01). (D) Dose response in miR-204-5p levels was observed in HEI-OC1 cells cultured with different doses of miR-204-5p inhibitor. (E) Introduction of a miR-204-5p inhibitor reversed the downregulation of the Bcl-2 mRNA level in HEI-OC1 cells transfected with si-HDAC2 (∗∗p < 0.01). (F) An example of western blot for relative Bcl-2 expression in HEI-OC1 cells treated with si-HDAC2 alone or si-HDAC2 plus miR-204-5p inhibitor. Representative images of western blot analysis of BcL2 expression in HEI-OC1 cells. (G) Densitometric analyses of western blot indicated a significant upregulation of Bcl-2 protein in HEI-OC1 cells co-transfected with si-HDAC2 and miR-204-5p inhibitor (∗p < 0.05, ∗∗p < 0.01). All data displayed as mean ± SD were obtained from three repeated and independent assays.
Fig 5: A miR-204-5p/Bcl-2-dependent manner in apoptosis of HEI-OC1 cells induced by the downregulation of HDAC2Rescue assays were conducted in HEI-OC1 cells transfected with different plasmids: scRNA, si-HDAC2, si-HDAC2+miR-204-5p inhibitor, si-HDAC2+Bcl-2, si-HDAC2+miR-204-5p inhibitor+Bcl-2. (A) Cell viability was assessed in HEI-OC1 cells transfected with different plasmids. The decreased cell viability of HEI-OC1 cells resulting from HDAC2 silencing was partially reversed by inhibition of miR-204-5p or overexpression of Bcl-2 (∗p < 0.05, ∗∗p < 0.01). (B) Flow cytometry analysis in HEI-OC cells transfected with indicated plasmids. (C) The increased incidence of apoptosis resulting from HDAC2 inhibition could be partially mitigated by either co-transfection with the miR-204-5p inhibitor or the Bcl-2 expression vector (∗p < 0.05, ∗∗p < 0.01). (D) Representative images of trypan blue staining in HEI-OC1 cells transfected with different plasmids. (E) Reduced cell survival rate induced by HDAC2 knockdown was partially reversed by miR-204-5p knockdown or Bcl-2 overexpression. Cell survival rate recovered to a normal level (scRNA control) after co-treatment with both miR-204-5p inhibitor and Bcl-2 under HDAC2 depletion (∗p < 0.05, ∗∗p < 0.01). (F) Representative images of TUNEL staining in transfected HEI-OC1 cells. (G) Increased numbers of apoptotic cells induced by HDAC2 knockdown were reversed by co-transfection with miR-204-5p inhibitor and/or Bcl-2 (∗p < 0.05, ∗∗p < 0.01). All data displayed as mean ± SD were obtained from three repeated and independent assays.
Supplier Page from Abcam for Anti-HDAC2 antibody